Juvenile Arthritis


The Financial Impact of Juvenile Idiopathic Arthritis

October 13, 2021

“Considering medical appointments, laboratory tests, medications, and indirect costs, juvenile idiopathic arthritis generates elevated costs, which results in a high economic impact for the family,” investigators stated.

Decrease in Pediatric Patient Telemedicine Visits During COVID-19 Pandemic

September 30, 2021

While telemedicine is a valuable tool to provide access to care for families seeking care within a small subspecialty with a limited supply of providers, there was a significantly lower amount of new pediatric patient visits in the beginning of the COVID-19 pandemic.

Majority of Patients With Juvenile Idiopathic Arthritis Achieved Clinical Remission

August 27, 2021

“Juvenile idiopathic arthritis constitutes a significant cause of disability and quality of life impairment in pediatric and adult patients,” investigators stated. “Recent advances in JIA treatment addressing more specific targets have led to better short and long-term disease outcomes."

Lower Anti-Vaccine Antibody Levels Observed in Patients With Juvenile Idiopathic Arthritis

July 28, 2021

Many children with juvenile idiopathic arthritis stop vaccinating when diagnosis is established, despite them being at a greater risk of infections than healthy children due to their aberrant immunity and the use of immunosuppressive drugs.

First-Line Biologics Reduce Glucocorticoid Exposure in Patients With Systemic Juvenile Idiopathic Arthritis

July 19, 2021

Investigators analyzed the effect of biologic therapies in order to determine the effectiveness of this first-line biologic approach in treating systemic juvenile idiopathic arthritis (sJIA) and reducing the exposure of glucocorticoids, a driver of morbidity in this patient population.

Safety and Efficacy of Secukinumab for Juvenile Idiopathic Arthritis

June 21, 2021

Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.